LARGON Drug Patent Profile
When do Largon patents expire, and what generic alternatives are available?
Largon is a drug marketed by Hikma and is included in one NDA.
The generic ingredient in LARGON is propiomazine hydrochloride. There is one drug master file entry for this compound. Additional details are available on the propiomazine hydrochloride profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for LARGON?
- What are the global sales for LARGON?
- What is Average Wholesale Price for LARGON?
Summary for LARGON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 15 |
| Patent Applications: | 50 |
| DailyMed Link: | LARGON at DailyMed |
US Patents and Regulatory Information for LARGON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hikma | LARGON | propiomazine hydrochloride | INJECTABLE;INJECTION | 012382-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
